Key result
Bivalirudin and glucocorticoids enable successful PCI in recurrent acute myocardial infarction with severe ITP.
Why the study?
Managing patients with immune thrombocytopenic purpura and thrombocytopenia presenting with acute myocardial infarction is challenging, especially with severe platelet decrease after intervention.
Case Report (n=1)
No
Patients with concurrent AMI and ITP can be safely managed with invasive percutaneous coronary intervention when combined with targeted anticoagulation (e.g., bivalirudin) and prompt steroid/IVIG therapy to manage dangerous platelet count drops.
Managing patients with immune thrombocytopenic purpura (ITP) and thrombocytopenia is challenging when they present with AMI, especially when platelets are severely decreased after interventional therapy. Our case shows that such patients, if stable, can be safely and successfully treated with glucocorticoid to improve platelet count after proceeding to invasive management and dual antiplatelet medications.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) conducted a case report in Acute Myocardial Infarction complicated with Idiopathic Thrombocytopenic Purpura (n=1). Percutaneous coronary intervention and glucocorticoids was evaluated on Platelet count recovery and clinical stability. A 59-year-old female with recurrent acute myocardial infarction and severe immune thrombocytopenic purpura was successfully treated with percutaneous coronary intervention, bivalirudin, and glucocorticoids.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: